Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
暂无分享，去创建一个
H. Beltran | S. Vallabhajosula | N. Bander | B. Faltas | S. Tagawa | A. Molina | S. Goldsmith | Y. Jhanwar | K. Ballman | C. Oromendia | J. Sreekumar | A. Hackett | M. J. Naiz | D. Nanus | J. Babich